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Background: To assess the responsiveness of the Cough and Sputum Assessment Questionnaire
(CASA-Q) in COPD and chronic bronchitis patients recovering from an acute exacerbation. The
20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and
sputum and their impact on everyday life in clinical (trial) settings. The four domains
(cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating
higher symptom/impact levels.
Methods: Outpatients were enrolled within 48 h of symptom onset of their exacerbation. Treat-
mentwas initiated at thediscretion of the investigator, andpatients observed for 6weeks. During
study visits, 59 eligible patients completed the CASA-Q at enrolment, week 1, 2 and 6. Respon-
siveness was assessed by calculating standardized effect sizes.
Results: Of the 19 male and 40 female patients with a mean (standard deviation, SD) age of 61.1
(10.5) years, all were classified by their physician to have improved or recovered after six weeks.
Themean (SD) CASA-Q sores for the cough symptom, cough impact, sputum symptomand sputum
impact domains increased from 32.6 (21.0), 40.7 (22.4), 37.4 (20.1), 47.1 (24.2) at enrolment to
54.0 (19.8), 63.7 (21.3), 55.1 (19.0), 65.5 (20.5) atweek 6, respectively. Standardizedeffect sizes132 77 93362; fax: þ49 6132 77 4233.
hringer-ingelheim.com (B.U. Monz).
9 Elsevier Ltd. All rights reserved.
CASA-Q in exacerbations 535for patients improved or recovered from their exacerbation at week 6 were above 1.0 for the
cough domains and at least 0.77 for the sputum domains.
Conclusions: The CASA-Q was responsive to symptom changes in patients recovering from an
exacerbation.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Current guidelines emphasize the role of symptom
management in the treatment of stable Chronic Obstructive
Pulmonary Disease (COPD).1 However, instruments evalu-
ating patient-reported sputum expectoration and cough,
assessing their impact on everyday life in this patient
population and consequently being responsiveness to
treatment effects targeted at those symptoms are limited.
We have developed and initially validated the Cough And
Sputum Assessment Questionnaire (CASA-Q) for use in COPD
and chronic (non obstructive) bronchitis patients.2 This 20-
item questionnaire assesses cough and sputum symptoms
and their impact by calculating four domain scores.
Although the questionnaire’s intended use is in stable
patients to assess the effects of maintenance treatment for
the relief of cough and sputum expectoration (i.e. not
symptom changes over the course of an exacerbations), the
current study aimed to explore the ‘maximal’ responsive-
ness of the CASA-Q during symptom resolution in COPD and
chronic bronchitis patients enrolled with an acute mild or
moderate exacerbation. This setting was chosen as there
are currently no available maintenance treatments that
reliably reduce symptoms of cough and sputum in COPD and
chronic bronchitis patients. During an exacerbation, those
symptoms change as patients may recover with treatment
(i.e. the underlying clinical construct being measured by
the CASA-Q is known to change). The purpose of the study
was therefore to evaluate the responsiveness of the CASA-Q
under conditions of known change. Because exacerbations
are defined as an acute worsening of the patients under-
lying condition, including cough and sputum, these events
are suitable to evaluate changes in CASA-Q scores between
the acute state, when these symptoms are more severe,
and following recovery as determined by the clinician and
other clinical parameters, when these symptoms should be
less severe.
A failure to reflect the observed improvement in the
clinical course of an exacerbation would therefore indicate
that the CASA-Q may be unsuitable for maintenance
treatment settings. The milder the exacerbation the more
likely the symptom changes will resemble symptom
improvements seen for stable patients receiving mainte-
nance therapy, hence the selection of mild and moderate
exacerbations as most relevant.
Exacerbations of COPD and chronic bronchitis are
a major cause of morbidity, mortality, and reduced health-
related quality of life.3e5 During exacerbations patients
suffer from increased respiratory symptoms such as dysp-
nea, cough and sputum expectoration.3 During the clinical
course of an exacerbation, symptoms increase, and,
depending on severity, lead patients to intensify their
respiratory medication or to seek care from a health careprofessional. Subsequent to treatment, symptoms decline
and may resolve to previous levels or may remain perma-
nently worse than before the event.6,7 While several
studies investigated the resolution of physiologic outcomes
or dyspnea, there is only limited information about patient-
reported resolution of cough and phlegm 7,8 and their
associated impact on well-being during recovery from acute
exacerbations of COPD or chronic bronchitis.9
Methods
Patients and setting
After IRB approval and written informed consent, female or
male patients 40 years or older with an investigator diag-
nosis of COPD or chronic bronchitis were enrolled at the
onset of a mild or moderate exacerbation (i.e. within 48 h
of symptoms). Exacerbations were defined as an increase or
new onset of at least two lower respiratory symptoms
related to COPD/chronic bronchitis, with at least one
symptom lasting for three or more days and requiring
a change in treatment. Lower respiratory symptoms
included: shortness of breath, sputum production (volume),
sputum purulence, cough, wheezing, and chest tightness. A
change in treatment required the prescription of antibiotics
and/or systemic steroids (moderate exacerbation) or
a significant change of prescribed respiratory medication
(mild exacerbation). Investigators had to confirm the
presence and time of onset of a mild or moderate exacer-
bation via a ‘verification’ case report form that queried all
parts of the definition individually. Severe exacerbations
were defined as those requiring hospitalisations and were
an exclusion criterion. Other exclusion criteria were
a history of asthma, cystic fibrosis, bronchiectasis, active
pneumonia or tuberculosis. Patients had to be current or
former smokers with a history of at least 10 pack-years.
Patients were followed for a total of 6 weeks, and had
clinical visits at day 1 (visit 1), day 8 (visit 2), day 15 (visit 3),
and day 43 (visit 4). At each clinical visit, the CASA-Q was
administered and the investigator assessed the clinical
course of the exacerbation. The patients received routine
medical treatment for their exacerbation at the discretion
of the investigator. Additionally, they were provided with
albuterol rescue medication. Spirometry with post-bron-
chodilator measurement of both the Forced Expiratory
Volume in 1 s (FEV-1) and Forced Vital Capacity (FVC) was
performed according to ATS standards 10 at the last visit in
order to characterize patients’ lung function. Arterial
oxygen saturation was assessed at every clinical visit via
pulse oximetry.
The study was conducted in seven study sites in the
United States, started in November 2007 and completed in
March 2008.
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The CASA-Q has been described in detail elsewhere.2
Briefly, the questionnaire was developed and initially vali-
dated to assess the symptoms of cough and sputum based
on the description of symptom frequency and severity, and
their impact on daily activities. The cough and sputum
domains have three items each, whereas the cough impact
domain consists of eight items, and the sputum impact
domain of six items (see appendix). Each item is answered
on a scale from ‘never’ to ‘always’ (for frequency) or from
‘not at all’ to ‘a lot/extremely’ (for intensity), each type
using five categories. All items are rescored from 1e5 to
0e4, and then reverse scored such that better responses
have higher scores. Within each domain, items are summed
and rescaled using the following algorithm: (sum rescored
items)/(range of rescored item sum) 100. This results in
CASA-Q domain scores that range from 0 to 100, with higher
scores associated with fewer symptoms/less impact due to
cough or sputum. No overall score is being calculated. The
CASA-Q is paper-administered and has a 7-day recall period.
This recall period was selected because of the chronic
nature of chronic bronchitis and COPD and the fact that
important impacts in patients in the intended setting (i.e.
maintenance treatment of cough and sputum symptoms) do
not happen on a daily basis but will likely be covered within
one week.
At the last visit, the patient-assessed symptom changes
since the enrolment visit by answering the question ‘Check
the one number that best describes how your cough and
phlegm symptoms are now, compared to the day you
started in the study’ on a 7-item response scale from ‘very
much better’ to ‘very much worse’ (Patient Global
Impression of Change, PGI-C).
Patients completed a daily symptom diary (for the
wording of the diary questions, please refer to footnote 2
under Table 2.), and documented their morning Peak
Expiratory Flow (PEF) rate and their number of puffs/day
of rescue medication during the entire study period. The
diary was used to monitor symptoms over time, supple-
menting the physician’s and patient’s assessments of
change in symptoms. This was done in order to demon-
strate that the underlying clinical construct which the
CASA-Q is supposed to measure would indeed change over
time as expected. Additionally, the cough and sputum
items of the diary were expected to correlate highly with
the respective cough and sputum symptom domains of the
CASA-Q (see below for analysis details), assessing the val-
idity of the CASA-Q.
Clinician-administered questionnaires
The assessment of the clinical course of the exacerbation
was recorded at each visit on a scale from ‘worse’, ‘no
improvement’, ‘improved’ or ‘recovered’, based on the
investigator’s judgment of the presenting patient’s respi-
ratory symptoms compared to the enrolment visit (Clinical
Assessment of Recovery, CAR). Similar to the PGI-C, the
investigator recorded at the last visit the clinician’s
impression of change with a corresponding question (Clini-
cian Global Impression of Change, CGI-C).Statistical analysis
For an approximation of the sample size, previously
observed standard deviations (SD) were utilized.2 For
a power of 90% to detect a within group difference in the
CASA-Q domain scores between enrolment and the last
study visit of 0.5 SD, 44 subjects were required. In order to
account for the unknown SD in an exacerbation setting, the
descriptive character of psychometric analyses and
patients discontinuing the study early, 65 were enrolled.
The mean CASA-Q domain scores were calculated for
each visit, overall and for patient subgroups of interest.
Such subgroups were patients classified as ‘improved’,
‘unchanged’ or ‘worse’ by any of the three relevantmeasures
(PGI-C, CGI-C, CAR). Aminimum sample size for any subgroup
analysis of 20 patients was pre-specified. Themaximal CASA-
Q score differences (i.e. change scores) were expected
betweenday 1 and 43, or day 8 and 43. The rationale for using
both differences, from day 1 and day 8 to day 43 is to ensure
capturing the ‘peak‘ of the exacerbation as the CASA-Q has
a 7-day recall period. CASA-Q data collected at the first visit
may partly reflect days where the patient was not (yet) in the
exacerbation as the inclusion criterion required a symptom
onset within 48 h of enrolment.
The primary analysis was pre-specified as assessing the
responsiveness of the four CASA-Q domain scores using
standardized effect sizes (SES), defined as the differences
in relevant scores divided by their pooled standard devia-
tion (SD). For this purpose, the mean change scores
between assessments (i.e. day 1/8 and day 43) were
calculated for each of the CASA-Q domains and patient
subgroups (see above for definition of groups). Then, each
mean change on the CASA-Q domain scores was converted
to an SES. An effect size between 0.20 (0.2 SD) and 0.49 is
considered as small, between 0.5 and 0.79 as medium, and
above 0.79 as large.11 P-values for SES were derived from
paired t-tests, testing mean SES differences from zero (with
p< 0.05 considered significant).
Mean changes in diary scores were calculated and tested
for statistical significance using a generalized linear model
for repeated measures for the morning PEF and rescue
medication, i.e. the ‘objective’ measures of the clinical
course of the exacerbation. Arterial oxygen saturation was
assessed with the same statistical model, including baseline
value as covariate.
Additionally, the CASA-Q cough symptom and sputum
symptom domain scores were correlated to their respective
diary item collected during the week corresponding to the
CASA-Q recall period (Pearson correlation coefficients). For
this purpose, 7-day means per patient were calculated for
the relevant diary items. This mean response was correlated
with the CASA-Q domains at days 8, 15, and 43. It was
expected that the CASA-Q cough symptoms and sputum
symptoms domains would correlate well with the diary items
pertaining specifically to those symptoms (‘How often did
you cough?‘ and ‘How often did you bring up phlegm?).
In a post-hoc analysis, CASA-Q scores were exploratory
stratified by smoking status (former vs. current). This analysis
was performedexpecting lower (i.e.worse) scores for smokers
for all domain scores of the CASA-Q compared to former
smokers. This additional analysis was supposed to support the
CASA-Q in exacerbations 537validity of the CASA-Q. All statistical analyses were performed
using SAS version 9.1 (SAS Institute Inc., Cary, NC).
Results
Patient disposition
In total, 65 patients were enrolled into the study. Six
patients were not eligible for analysis (study discontinua-
tion (nZ 3), hospitalisation (nZ 2), concomitant lung
cancer (nZ 1)). Thus, 59 patients were analyzed (Table 1).
Mean (standard deviation) disease duration was 5.5 (4.5) or
7.5 (5.0) years for patients with chronic bronchitis or COPD,
respectively. By the trial exacerbation definition (see in
‘methods’), all patients presented with a moderate exac-
erbation, receiving either oral steroids (nZ 53, 90%),
antibiotics (nZ 49; 83%), or both. No patient presented
with a mild exacerbation.
Clinical course
According to the physician’s assessment (CAR), 17%, 66%
and 17% of patients were ‘worse/not improved’, ‘improved’
or ‘recovered’, respectively, after eight days in the study.
At day 43, this distribution changed to 83% in the ‘recov-
ered’ and the remaining 17% in the ‘improved’ category. Six
weeks after enrolment, the majority of patients were
assessed as recovered from the exacerbation.
The course of the exacerbation according to patients’
diary scores, morning PEF and rescue medication use is
shown in Table 2. Mean weekly PEF increased from the
week preceding day 8 to the week preceding day 43 byTable 1 Patient characteristics.
Patient sample
At enrolment (n) 59
Investigator diagnosis
of COPD/chronic bronchitis [n(%)]
54/5 (92/8)
Mean (SD) age [years] 61.1 (10.5)
Male/female gender [n(%)] 19/40 (32/68)
Caucasian origin [%] 95
Smoking history [n(%)]
Former smoker 27 (46)
Smoker 32 (54)
Mean (SD) smoking history [pack-years] 60.14 (30.12)
Lung function at day 43 (n)a 57b
Mean FEV-1 (SD) [L] 1.47 (0.77)
FEV-1% predicted 56.4 (25.5)
Mean FVC (SD) [L] 2.41 (0.84)
COPD classification [n(%)]c
Not obstructed 19 (33)
Mild 2 (4)
Moderate 14 (25)
Severe 13 (23)
Very severe 9 (16)
a All post-bronchodilator values.
b Two patients with missing lung function measurements.
c May not add up to 100% due to rounding.10 L/min (not statistically significant); rescue medication
use significantly decreased in the corresponding interval
(pZ 0.0263). Mean arterial oxygen saturation assessed by
pulse oximetry increased from enrolment with 94.3% to
95.9% at day 43 (pZ 0.0397).
CASA-Q responsiveness
Descriptively, in parallel with the clinical course of the
exacerbation, the mean cough and sputum symptom and
impact domain scores of the CASA-Q increased from day 1
to day 15 and remained then approximately the same until
day 43 (Fig. 1).
All CASA-Q domain scores demonstrated responsiveness
between day 1e43 and day 8e43 for all three assessment
scales used to define ‘improved’ patient groups (i.e. using
the PGI-C, CGI-C and the CAR). Table 3 demonstrates the
SESs for CASA-Q change scores between initial presentation
and the last visit above 1.0 for the cough domains, and
between 0.77 and 0.92 for the sputum domains. Effect sizes
calculated between day 8 and day 43 were lower, but still
between 0.34 and 0.65. Both analyses used the PGI-C and
CGI-C to define ‘improved’. Results for the CAR were in the
same order of magnitude (data not shown). There were not
enough patients (i.e. <20) to allow for comparable analyses
in patients classified as ‘unchanged’ or ‘worse’.
Mean CASA-Q change scores between day 1 and 43
categorized by all PGI-C response options increased with
improving categories (Table 4). For the ‘a little better’
category, changes in the cough domain scores were
approximately twice as large as for the corresponding
sputum domains scores.
CASA-Q validation
Pearson correlation coefficients between the cough and
sputum diary items and the respective CASA-Q symptom
domain scores were moderate to high, and ranged from
j0.620j to j0.685j at day 8, j0.690j to j0.746j at day 15 and
lastly, j0.599j to j0.801j at day 43. All correlations were
statistically significant (p< 0.0001).Table 2 Patient daily diarya parameters (nZ 59).
Day 8 Day 15 Day 43
Morning Peak
Flow (L/min)
217.5
(82.99)
226.1
(81.41)
227.5
(95.26)
Rescue medication
(number of
puffs in 24 h)b
3.0 (2.89)
/2.4
2.9 (2.92)
/2.2
2.4 (2.43)
/1.9
Breathlessness 3.2 (0.80) 2.9 (0.79) 2.9 (0.82)
Cough 3.3 (0.70) 3.0 (0.77) 2.9 (0.76)
Sputum 2.9 (0.86) 2.8 (0.94) 2.7 (0.90)
a All diary items: Weekly mean (SD) score for the 7 days
preceding the clinical visit. Respective questions on breath-
lessness, cough and sputum for the preceding 24 h period were:
‘How short of breath were you?’, ‘How often did you cough?’,
‘How often did you bring up phlegm?’ on a scale from 1 to 5
(‘not at all/never’ to ‘a lot/always’).
b Mean (SD)/median.
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Figure 1 Mean CASA-Q domain scores by day. Higher CASA-Q
domain scores are associated with fewer incidents/implica-
tions due to cough or sputum. Scores range from 0 to 100.
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former smokers differed in the cough domains by at least 11
and up to 21 points, and in the sputum domains by at least 8
and up to 20 points (Fig. 2). Corresponding domain scores
were always lower for current than for former smokers,
indicating a higher symptom severity and impact of both
cough and sputum. However, due to small sample sizes per
stratum (nZ 27 former smokers, nZ 32 current smoker),
those results have to be considered exploratory.
Discussion
This study assessed the responsiveness of the CASA-Q,
a new 20-item questionnaire designed to measure the
severity and impact of cough and sputum in patients with
COPD and chronic bronchitis. The exacerbation setting was
used as patients will present with cough and sputum
symptoms (i.e. those symptoms are part of the definition of
an exacerbation) that would decline over time, as the
event resolves. Multiple clinical and patient-reportedTable 3 Responsiveness: Mean change scores and Standardised
day 43 according to the Patient (nZ 57) and Clinician Global Imp
Change scores between day 1 and 43
Mean SD SESa P val
Patient Global Impression of Change
Cough symptoms 21.93 21.28 1.04 <0.0
Cough impact 23.36 19.61 1.04 <0.0
Sputum symptoms 17.98 20.82 0.88 <0.0
Sputum impact 18.86 19.21 0.77 <0.0
Clinician Global Impression of Change
Cough symptoms 21.70 21.29 1.03 <0.0
Cough impact 23.44 19.30 1.04 <0.0
Sputum symptoms 18.39 19.98 0.92 <0.0
Sputum impact 19.04 18.50 0.78 <0.0
a Within group standardized effect sizes (SES) calculated as mean ch
at first time point.
b P-values are derived from paired t-tests testing mean SES differenmeasures were used to confirm the presence of heightened
symptoms on day 1 (enrollment) and that patient
improvement had taken place at subsequent CASA-Q
assessments (days 8, 15 and 43).
The CASA-Q was able to measure changes between the
patient presentation and subsequent visits in all of its four
domains. Patients’ coughand sputumsymptomsaswell as their
impact improved consistently during the first two weeks after
initial presentation and initiation of treatment. Thereafter,
however, patients generally did not report any additional
improvements in cough and sputum symptoms or impact of
thoseontheCASA-Q,possibly indicating theirusual impairment
level due to the underlying chronic respiratory disease.
This course of symptom resolution was consistent with
earlier findings by Seemungal et al. who reported a median
time to recovery of 7 (range 4e14) days for symptoms and of
6 (range 1e14) days for PEF.12 The median PEF decrease of
6.6 L/min reported from another exacerbation study by
these authors was comparable to what was obtained in the
present study.3 Recently, Vijayasaratha and Stockley
described different symptom lengths for treated exacerba-
tions of COPD ranging from a mean of 12 days for patients’
subjective return to pre-exacerbation symptom levels, to 14
days for resolution of sputum color and volume.13 Spencer
et al. used the St George’s Respiratory Questionnaire (SGRQ)
to evaluate the health status of patients presenting with an
acute exacerbation of chronic bronchitis and found the
greatest improvement occurring within the first 4 weeks.14
Since the SGRQ is measuring different concepts than the
CASA-Q and is often administered with a recall period of four
weeks, their findings are not inconsistent with ours. Another
group has developed a daily measure, the breathlessness,
cough, and sputum scale (BCSS), a brief, three-item,
patient-reported outcomemeasure that has been developed
to evaluate symptomatic improvement in patients with
COPD but does not assess the impact of symptoms on
patients’ well-being.7,8 They were able to document with
the BCSS a symptom increase and decreasewithin seven days
of the exacerbation. Score changes of the BCSS for moderate
exacerbations were approximately 16% of the maximal
score.Effect Sizes of the CASA-Q domains for patients ‘Improved’ at
ression of Change (nZ 58).
Change scores between day 8 and 43
ueb Mean SD SESa P valueb
001 12.72 18.77 0.64 <0.0001
001 15.02 18.31 0.65 <0.0001
001 7.89 15.06 0.38 0.0002
001 11.33 18.78 0.47 <0.0001
001 11.93 19.57 0.59 <0.0001
001 14.60 18.69 0.62 <0.0001
001 7.18 15.72 0.34 0.0010
001 11.14 18.62 0.45 <0.0001
ange score between two time points divided by standard deviation
ces from zero.
Table 4 Mean CASA-Q change score by patient assessment of change category.
PGI-C Response n Mean change in CASA-Q domain score (SD) between day 1 and 43
Cough symptom Cough impact Sputum symptom Sputum impact
Very much better 18 26.9 (21.30) 28.6 (21.28) 27.8 (18.96) 25.5 (22.41)
Much better 18 19.4 (22.51) 22.9 (19.41) 18.5 (22.06) 19.4 (14.92)
A little better 21 19.8 (20.49) 19.2 (18.09) 9.1 (18.05) 12.7 (18.37)
No change 1 e e e e
A little worse 1 e e e e
Much worse 0 e e e e
Very much worse 0 e e e e
Total 59 21.3 (21.29) 23.0 (19.44) 17.7 (20.59) 18.4 (19.06)
CASA-Q in exacerbations 539For the CASA-Q, all calculated standardized effect sizes
were large. This is attributable to the clinical setting
(maintenance treatment of relatively stable patients versus
patients with an acute exacerbation), rather than neces-
sarily a characteristic of the CASA-Q. The CASA-Q will need
to be investigated in an interventional maintenance
therapy setting to assess the responsiveness.15 The change
scores derived in this study could be considered the
maximal responsiveness of the scale.0 10 20
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Figure 2 CASA-Q domain scores by day, stratified by smoking stat
sputum domains. Higher CASA-Q domain scores are associated with
range from 0 to 100.This study furthermore supported the validity of the
CASA-Q by showing that active smokers reported a more
intense severity of both cough and sputum and their impact
than former smokers during an acute exacerbation and
throughout its resolution. The Lung Health Study revealed
a lower prevalence of chronic sputum expectoration and
cough in sustained quitters from smoking, suggesting some
reversibility of smoke-induced airway changes.16 Accord-
ingly, a reduction of bronchial epithelial mucin stores and30 40
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540 B.U. Monz et al.squamous cell metaplasia in former smokers was obvious
when compared to current smokers.17 The present study
indicated that patient-reported cough and sputum are
distinct between smokers and former smokers even during
acute exacerbations of COPD and chronic bronchitis.
A possible limitation of this study was the inherent
inability to characterize patients by spirometry at study
entry. Thus, we obtained some discordance between clini-
cian diagnosis of COPD or chronic bronchitis at enrollment
and post-bronchodilator spirometry at the study end.
However, spirometry is still uncommonly used for the
diagnosis of COPD in managed care plans in the US,18 and
some inaccuracy of COPD diagnosis has been reported from
studies utilizing post-bronchodilator pulmonary function
testing.19,20 However, as the CASA-Q has been developed
and validated in both patient groups, whether obstructed
or not, this is not a limitation for assessing the respon-
siveness of the instrument. Another aspect that will need
further investigation was the lack of discrimination of the
CASA-Q cough domains between patient-assessed
improvement where comparable change scores were
observed for the ‘a little better’ and the ‘much better’
category. In a previous validation study, we could not find
a strong correlation between cough measured via a unidi-
rectional contact microphone and respiratory inductance
plethysmography and the CASA-Q cough domains.2 Both of
these findings may indicate that cough could be particularly
difficult to measure, possible due to patients getting used
to their cough and adopting certain coping mechanisms.
In conclusion, the CASA-Q exhibited the ability to detect
changes in cough and sputum symptoms and their impact in
patients recovering from an exacerbation of COPD or
chronic bronchitis. Based on these findings, the CASA-Q will
need to be further evaluated in an interventional setting of
relatively stable patients to establish its responsiveness in
this patient population.
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ch item is answered ranging from ‘‘never‘‘ to
lways‘‘ or from ‘‘not at all‘‘ to ‘‘a lot/extremely‘‘ as
plicable; each type using five categories.
er the last 7 days,
1. How much did you cough when you woke up in the
morning?
2. How often did you cough during the day?
3. How often did you have coughing bouts?
4. How often were you tired after coughing?
5. How often did coughing make you short of breath?
6. How annoyed were you by your cough?
7. How often did you avoid going to public places
because of your cough (for example, movie
theaters, restaurants, etc)?
8. How often were your usual activities interrupted
by your cough (for example, driving, hobbies,
working around the house)?
9. How often did your cough interrupt your conver-
sations with others (for example, phone conver-
sations and face-to-face)?
10. How often did your cough wake you up, prevent
you from falling asleep or falling back to sleep?
11. How often were you uncomfortable about both-
ering other people while coughing?
12. How thick was your phlegm?
13. How often did you bring up phlegm?
14. How often did your phlegm make it difficult for
you to breathe?
15. How difficult was it for you to bring up phlegm?
16. How often did you feel uncomfortable about
bothering other people while bringing up phlegm?
17. How annoyed were you by your phlegm?
18. How often did your phlegm interfere with your
ability to speak?
19. How often did your phlegm prevent you from going
to public places (for example, movie theaters,
restaurants, etc)?
20. How often did you have to interrupt your usual
activities to get rid of your phlegm (for example,
driving, hobbies, working around the house)?
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